Systemic bevacizumab for simultaneous treatment of cancer and choroidal neovascularisation.
A 47-year-old woman with a medical history of pseudoxanthoma elasticum and associated choroidal neovascularisation that was successfully managed with intravitreal bevacizumab injections developed non-squamous non-small cell lung carcinoma. The patient's oncological medication regimen included systemic bevacizumab. During the 22 months that the patient received systemic bevacizumab for management of her malignancy, intravitreal bevacizumab injections were held and the patient's visual acuity remained stable and the subretinal space was free of fluid leakage.
Medical and Surgical Eyesite, Brooklyn, New York, USA Department of Ophthalmology, St. Johns Episcopal Hospital, Far Rockaway, New York, USA.
Norman
N
Saffra
Department of Ophthalmology, St. Johns Episcopal Hospital, Far Rockaway, New York, USA.
Benjamin
B
Reinherz
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000188:drug therapy*; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy*; D004333:Drug Administration Routes; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D011561:Pseudoxanthoma Elasticum / Q000150:complications; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab